Clinical Trial Update: NOX-E36 First-in-Human (FIH) Study [Phase 1]

View source ↗

Summary

A first-in-human Phase 1 trial of NOX-E36 by TME Pharma has completed, reporting initial safety and tolerability data across inflammatory-related indications in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus
• Type 2 Diabetes Mellitus

Drugs mentioned

• NOX-E36

Snippet

Sponsor: TME Pharma AG | Conditions: Chronic Inflammatory Diseases, Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED